[go: up one dir, main page]

MX2010006443A - TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES. - Google Patents

TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.

Info

Publication number
MX2010006443A
MX2010006443A MX2010006443A MX2010006443A MX2010006443A MX 2010006443 A MX2010006443 A MX 2010006443A MX 2010006443 A MX2010006443 A MX 2010006443A MX 2010006443 A MX2010006443 A MX 2010006443A MX 2010006443 A MX2010006443 A MX 2010006443A
Authority
MX
Mexico
Prior art keywords
heart disease
blockers
treatment
reversing
animals
Prior art date
Application number
MX2010006443A
Other languages
English (en)
Inventor
Gerald Beddies
Axel Schmidt
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2010006443A publication Critical patent/MX2010006443A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para revertir la remodelación cardiaca electrofisiológica de animales con cardiopatía. Más específicamente, el procedimiento incluye administrar a un animal que lo necesite un bloqueante de adrenoceptores ß.
MX2010006443A 2007-12-27 2008-12-19 TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES. MX2010006443A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1689107P 2007-12-27 2007-12-27
PCT/EP2008/010892 WO2009083177A1 (en) 2007-12-27 2008-12-19 TREATMENT OF HEART DISEASE USING β-BLOCKERS

Publications (1)

Publication Number Publication Date
MX2010006443A true MX2010006443A (es) 2010-09-03

Family

ID=40456577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006443A MX2010006443A (es) 2007-12-27 2008-12-19 TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.

Country Status (19)

Country Link
US (1) US20100305213A1 (es)
EP (1) EP2234609A1 (es)
JP (1) JP2011507918A (es)
KR (1) KR20100102640A (es)
CN (1) CN101909612A (es)
AU (1) AU2008342250A1 (es)
BR (1) BRPI0821483A2 (es)
CA (1) CA2710665A1 (es)
CO (1) CO6300936A2 (es)
CR (1) CR11501A (es)
EC (1) ECSP10010249A (es)
IL (1) IL205870A0 (es)
MX (1) MX2010006443A (es)
NI (1) NI201000096A (es)
RU (1) RU2010131022A (es)
SV (1) SV2010003595A (es)
TW (1) TW200942227A (es)
WO (1) WO2009083177A1 (es)
ZA (1) ZA201003867B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113148A1 (zh) * 2012-01-30 2013-08-08 Lin Shuguang β3肾上腺素受体阻滞剂的抗肿瘤用途
DK3265126T3 (da) 2015-03-03 2021-09-13 Saniona As Kombinationsformulering af tesofensin og metoprolol
US11235029B2 (en) 2017-03-09 2022-02-01 Temple University-Of The Commonwealth System of Higher Methods for treating heart failure with a TRKB agonist
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
CN110269938A (zh) * 2019-06-27 2019-09-24 山东省眼科研究所 一种减轻铜绿假单胞菌性角膜炎症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung

Also Published As

Publication number Publication date
SV2010003595A (es) 2011-01-14
KR20100102640A (ko) 2010-09-24
JP2011507918A (ja) 2011-03-10
IL205870A0 (en) 2010-11-30
US20100305213A1 (en) 2010-12-02
NI201000096A (es) 2011-03-23
CA2710665A1 (en) 2009-07-09
ECSP10010249A (es) 2010-07-30
EP2234609A1 (en) 2010-10-06
CN101909612A (zh) 2010-12-08
WO2009083177A1 (en) 2009-07-09
ZA201003867B (en) 2011-08-31
CO6300936A2 (es) 2011-07-21
RU2010131022A (ru) 2012-02-10
TW200942227A (en) 2009-10-16
AU2008342250A1 (en) 2009-07-09
CR11501A (es) 2010-11-12
BRPI0821483A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MX382520B (es) Compuestos de pirimidinodiona contra estados cardiacos.
CL2008002110A1 (es) Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus.
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
CR20130418A (es) Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
PL2376537T3 (pl) Ludzkie przeciwciała przeciwko ludzkiemu czynnikowi tkankowemu
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EP4410976A3 (en) Methods of using zscan4 for rejuvenating human cells
PL2049127T3 (pl) N-metanokarbapochodne do leczenia chorób serca
WO2009149106A3 (en) Microparticles for the treatment of disease
EA201100755A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
CY1115136T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.
EA201270176A1 (ru) Производные тазаротена
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
BRPI0922736A2 (pt) sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
WO2010011599A3 (en) Pimethixene derivatives for promoting bone growth

Legal Events

Date Code Title Description
FA Abandonment or withdrawal